
Biagio Ricciuti, MD, PhD
Languages Spoken
ItalianContact Information
Office Phone Number
Fax
Appointments
On This Page
Biography
Biagio Ricciuti, MD, PhD
Dr. Biagio Ricciuti is a thoracic medical oncologist and scientist at the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute. His approach to patient care is informed by his clinical and translational research, that focuses on personalized cancer medicine. Dr. Ricciuti’s research aims to uncover the mechanisms of response and resistance to immunotherapies and targeted therapies in non-small cell lung cancer, advancing new treatment strategies that can benefit his patients.
He collaborates closely with specialists across oncology disciplines, including radiology, pathology, and surgery, ensuring each patient receives a comprehensive, multidisciplinary approach to care. Dr. Ricciuti is also actively involved in clinical trials and aims to optimize care by tailoring treatment plans to each patient’s unique tumor biology and clinical profile.
Researcher
Physician
Centers/Programs
Clinical Interests
Immunotherapies, Non-small cell lung cancer, Targeted therapies
Fellowship
- Dana-Farber Cancer Institute
- Santa Maria della Misericordia Hospital
Residency
- Santa Maria della Misericordia Hospital
Medical School
- Perugia University Medical School
Recent Awards
- Merit Award ASCO, 2019, 2021, 2022
- AACR SIT Award
- Young Investigator Award (YIA) ASCO, 2020
- Young Investigator Award (YIA) IASLC, 2020, 2024
- SITC-AstraZeneca Immunotherapy in Lung Cancer Clinical YIA, 2022
- Young Investigator Award (YIA), SITC, 2022
- 40 under 40 Emerging Leaders in Cancer Award, 2023
Publications
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471. View in: Pubmed
-
Response to Crizotinib After Entrectinib Resistance in ROS1-Rearranged, MET-Amplified Lung Adenocarcinoma. JCO Precis Oncol. 2024 Oct; 8:e2400394. View in: Pubmed
-
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy. Clin Cancer Res. 2024 Oct 01; 30(19):4397-4411. View in: Pubmed
-
Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans. bioRxiv. 2024 Sep 19. View in: Pubmed
-
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nat Commun. 2024 Aug 30; 15(1):7554. View in: Pubmed
-
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors. Cancer Discov. 2024 Aug 02; 14(8):1440-1456. View in: Pubmed
-
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. Cell Rep Med. 2024 Aug 20; 5(8):101663. View in: Pubmed
-
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Ann Oncol. 2024 Oct; 35(10):902-913. View in: Pubmed
-
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancer. HGG Adv. 2024 Jul 18; 5(3):100320. View in: Pubmed
-
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers. Nat Commun. 2024 Jun 14; 15(1):5110. View in: Pubmed
-
Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC. J Thorac Oncol. 2024 Jun; 19(6):877-882. View in: Pubmed
-
Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy. JAMA Oncol. 2024 Jun 01; 10(6):773-783. View in: Pubmed
-
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials. Oncologist. 2024 May 03; 29(5):422-430. View in: Pubmed
-
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (=90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab. JTO Clin Res Rep. 2024 Sep; 5(9):100675. View in: Pubmed
-
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities. Ann Oncol. 2024 Jun; 35(6):508-522. View in: Pubmed
-
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors. JCO Precis Oncol. 2024 Feb; 8:e2300439. View in: Pubmed
-
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2024 Feb; 8:e2300371. View in: Pubmed
-
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers. Res Sq. 2024 Jan 17. View in: Pubmed
-
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 10; 42(11):1311-1321. View in: Pubmed
-
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. J Immunother Cancer. 2023 11; 11(11). View in: Pubmed
-
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 11 01; 29(21):4408-4418. View in: Pubmed
-
Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden. Cancer Cell. 2023 10 09; 41(10):1731-1748.e8. View in: Pubmed
-
Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 09 15; 29(18):3579-3591. View in: Pubmed
-
Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib. JCO Precis Oncol. 2023 09; 7:e2300295. View in: Pubmed
-
Federated benchmarking of medical artificial intelligence with MedPerf. Nat Mach Intell. 2023 Jul; 5(7):799-810. View in: Pubmed
-
Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC. Nat Commun. 2023 07 15; 14(1):4238. View in: Pubmed
-
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571. View in: Pubmed
-
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 07 05; 29(13):2540-2550. View in: Pubmed
-
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort study. J Immunother Cancer. 2023 07; 11(7). View in: Pubmed
-
Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer. Curr Oncol Rep. 2023 09; 25(9):1017-1029. View in: Pubmed
-
Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023 08; 20(8):558-576. View in: Pubmed
-
Letter to the Editor: Reply to Zhao, Wu, and Ma. J Thorac Oncol. 2023 06; 18(6):e61-e62. View in: Pubmed
-
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023 11; 18(11):1524-1537. View in: Pubmed
-
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks. Drugs Context. 2023; 12. View in: Pubmed
-
Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. Eur Radiol. 2023 Oct; 33(10):7284-7293. View in: Pubmed
-
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet. 2023 05; 55(5):807-819. View in: Pubmed
-
Increased Tumor Mutation Burden Levels and Sensitivity of Non-Small Cell Lung Cancer to PD-L1 Blockade-Reply. JAMA Oncol. 2023 04 01; 9(4):570-571. View in: Pubmed
-
Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers-The Hunt for Predictive Biomarkers to Optimize Treatment Selection. JAMA Oncol. 2023 03 01; 9(3):353-354. View in: Pubmed
-
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC. J Thorac Oncol. 2023 06; 18(6):731-743. View in: Pubmed
-
Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With KRASG12C-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 02; 7:e2200621. View in: Pubmed
-
Immune-Related Thyroiditis in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors: Imaging Features and Clinical Implications. Cancers (Basel). 2023 Jan 20; 15(3). View in: Pubmed
-
The Anti-Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers. J Thorac Oncol. 2023 01; 18(1):17-20. View in: Pubmed
-
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC. JAMA Oncol. 2023 01 01; 9(1):51-60. View in: Pubmed
-
Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022 12; 28(12):2584-2591. View in: Pubmed
-
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma. Ann Oncol. 2023 03; 34(3):275-288. View in: Pubmed
-
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer. Drugs Context. 2022; 11. View in: Pubmed
-
Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers. Cancer Res. 2022 11 02; 82(21):4058-4078. View in: Pubmed
-
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease. Drugs Context. 2022; 11. View in: Pubmed
-
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions. Ann Oncol. 2022 11; 33(11):1202-1204. View in: Pubmed
-
Non-small-cell lung cancer: how to manage EGFR-mutated disease. Drugs Context. 2022; 11. View in: Pubmed
-
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol. 2022 08 01; 8(8):1160-1168. View in: Pubmed
-
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease. Drugs Context. 2022; 11. View in: Pubmed
-
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040. View in: Pubmed
-
Non-small-cell lung cancer: how to manage RET-positive disease. Drugs Context. 2022; 11. View in: Pubmed
-
Advanced non-small-cell lung cancer: how to manage non-oncogene disease. Drugs Context. 2022; 11. View in: Pubmed
-
Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022 08 15; 128(16):3067-3079. View in: Pubmed
-
Reply to Kus and Aktas. J Thorac Oncol. 2022 06; 17(6):e64-e65. View in: Pubmed
-
Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 04 14; 28(8):1640-1650. View in: Pubmed
-
Response to Hopkins, Kichenadasse, Logan, et al. J Natl Cancer Inst. 2022 03 08; 114(3):477-478. View in: Pubmed
-
Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities. Tumori. 2023 Feb; 109(1):105-111. View in: Pubmed
-
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations. J Immunother Cancer. 2022 02; 10(2). View in: Pubmed
-
Association between immune-related adverse event timing and treatment outcomes. Oncoimmunology. 2022; 11(1):2017162. View in: Pubmed
-
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. JAMA Oncol. 2021 Dec 01; 7(12):1856-1861. View in: Pubmed
-
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1761-1769. View in: Pubmed
-
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022 03; 17(3):399-410. View in: Pubmed
-
Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO Precis Oncol. 2021 11; 5:726-732. View in: Pubmed
-
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J Immunother Cancer. 2021 11; 9(11). View in: Pubmed
-
Axillary Lymphadenopathy After Coronavirus Disease 2019 Vaccinations in Patients With Thoracic Malignancy: Incidence, Predisposing Factors, and Imaging Characteristics. J Thorac Oncol. 2022 01; 17(1):154-159. View in: Pubmed
-
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 2021 11; 32(11):1391-1399. View in: Pubmed
-
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. J Thorac Oncol. 2021 07; 16(7):1176-1187. View in: Pubmed
-
Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. Genes (Basel). 2021 06 29; 12(7). View in: Pubmed
-
Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. Tumori. 2022 Jun; 108(3):250-257. View in: Pubmed
-
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma. Transl Lung Cancer Res. 2021 Apr; 10(4):1857-1872. View in: Pubmed
-
Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials. Sci Rep. 2021 03 23; 11(1):6637. View in: Pubmed
-
Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 5. View in: Pubmed
-
Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer. Cancer Res. 2021 05 01; 81(9):2566-2573. View in: Pubmed
-
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer. 2021 03; 9(3). View in: Pubmed
-
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol. 2020 12 01; 6(12):1952-1956. View in: Pubmed
-
Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). Transl Lung Cancer Res. 2020 Dec; 9(6):2428-2439. View in: Pubmed
-
Reply to Cortellini A. JTO Clin Res Rep. 2020 Nov; 1(4):100095. View in: Pubmed
-
What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer? Cancer J. 2020 Nov/Dec; 26(6):485-495. View in: Pubmed
-
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer. 2020 10; 8(2). View in: Pubmed
-
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression = 50%: a multicenter study with external validation. J Immunother Cancer. 2020 10; 8(2). View in: Pubmed
-
Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol. 2020 Nov; 132:109275. View in: Pubmed
-
Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2). View in: Pubmed
-
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clin Res Rep. 2020 Nov; 1(4):100074. View in: Pubmed
-
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother. 2020 07; 69(7):1189. View in: Pubmed
-
Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a Patient With MET Exon 14-Mutant NSCLC. JTO Clin Res Rep. 2020 Nov; 1(4):100072. View in: Pubmed
-
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression = 50% and Their Relationship With Clinical Outcomes. Clin Lung Cancer. 2020 11; 21(6):498-508.e2. View in: Pubmed
-
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. Future Oncol. 2020 Aug; 16(23):1751-1766. View in: Pubmed
-
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of =?50. Cancer Immunol Immunother. 2020 Nov; 69(11):2209-2221. View in: Pubmed
-
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. Eur J Cancer. 2020 07; 134:19-28. View in: Pubmed
-
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020 06; 31(6):807-814. View in: Pubmed
-
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4135-4142. View in: Pubmed
-
Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. Clin Lung Cancer. 2020 09; 21(5):e478-e487. View in: Pubmed
-
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother. 2020 Jul; 69(7):1177-1187. View in: Pubmed
-
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Eur J Cancer. 2020 03; 128:17-26. View in: Pubmed
-
Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. Lung Cancer. 2020 07; 145:181-185. View in: Pubmed
-
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020 06 01; 26(11):2615-2625. View in: Pubmed
-
Antibody-drug conjugates for lung cancer in the era of personalized oncology. Semin Cancer Biol. 2021 02; 69:268-278. View in: Pubmed
-
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. Lung Cancer. 2020 02; 140:59-64. View in: Pubmed
-
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 03; 31(3):404-411. View in: Pubmed
-
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. J Clin Oncol. 2020 02 20; 38(6):576-583. View in: Pubmed
-
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). Transl Lung Cancer Res. 2019 Dec; 8(6):1163-1173. View in: Pubmed
-
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: an effective but still broken option. Transl Lung Cancer Res. 2019 Dec; 8(Suppl 4):S378-S382. View in: Pubmed
-
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3. View in: Pubmed
-
Reply to J. Delyon et al. J Clin Oncol. 2019 12 20; 37(36):3564-3565. View in: Pubmed
-
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 10 01; 30(10):1653-1659. View in: Pubmed
-
Impact of performance status and age on osimertinib efficacy in patients with EGFR-mutant T790M-positive non-small-cell lung cancer. J Thorac Dis. 2019 Sep; 11(Suppl 15):S1831-S1834. View in: Pubmed
-
Emerging Biomarkers in the Era of Personalized Cancer Medicine. Dis Markers. 2019; 2019:5907238. View in: Pubmed
-
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes. Clin Transl Oncol. 2020 Jun; 22(6):844-851. View in: Pubmed
-
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. Clin Transl Oncol. 2020 May; 22(5):708-716. View in: Pubmed
-
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). Clin Lung Cancer. 2020 01; 21(1):15-20. View in: Pubmed
-
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 08 01; 37(22):1927-1934. View in: Pubmed
-
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. J Clin Oncol. 2019 10 20; 37(30):2738-2745. View in: Pubmed
-
Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence. Onco Targets Ther. 2019; 12:3171-3179. View in: Pubmed
-
A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients. Transl Lung Cancer Res. 2019 Apr; 8(2):135-143. View in: Pubmed
-
Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87. View in: Pubmed
-
Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives. J Thorac Dis. 2019 Mar; 11(Suppl 3):S249-S252. View in: Pubmed
-
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019 02 27; 7(1):57. View in: Pubmed
-
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. Clin Lung Cancer. 2019 05; 20(3):178-185.e2. View in: Pubmed
-
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist. 2019 06; 24(6):e327-e337. View in: Pubmed
-
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clin Lung Cancer. 2019 07; 20(4):237-247.e1. View in: Pubmed
-
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. Pharmacol Ther. 2019 04; 196:105-116. View in: Pubmed
-
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019 Feb; 145(2):479-485. View in: Pubmed
-
High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art. Trends Endocrinol Metab. 2019 01; 30(1):12-24. View in: Pubmed
-
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib. J Thorac Oncol. 2018 11; 13(11):e220-e222. View in: Pubmed
-
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer. Mol Clin Oncol. 2018 Dec; 9(6):689-696. View in: Pubmed
-
Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation. J Thorac Oncol. 2018 08; 13(8):e145-e147. View in: Pubmed
-
High density lipoprotein cholesterol and cancer: Marker or causative? Prog Lipid Res. 2018 07; 71:54-69. View in: Pubmed
-
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib. Med Oncol. 2018 Apr 17; 35(5):72. View in: Pubmed
-
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations. Lung Cancer. 2018 06; 120:70-74. View in: Pubmed
-
First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC. Transl Lung Cancer Res. 2018 Apr; 7(Suppl 2):S127-S130. View in: Pubmed
-
Osimertinib. Recent Results Cancer Res. 2018; 211:257-276. View in: Pubmed
-
Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma. J Thorac Oncol. 2018 01; 13(1):e9-e12. View in: Pubmed
-
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience. Ther Adv Respir Dis. 2018 Jan-Dec; 12:1753466618808659. View in: Pubmed
-
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? Thromb Res. 2018 03; 163:51-53. View in: Pubmed
-
Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications. Med Oncol. 2017 Dec 04; 35(1):4. View in: Pubmed
-
Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy. Semin Cancer Biol. 2019 06; 56:87-99. View in: Pubmed
-
Endothelial and cardiac progenitor cells for cardiovascular repair: A controversial paradigm in cell therapy. Pharmacol Ther. 2018 01; 181:156-168. View in: Pubmed
-
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer. Mayo Clin Proc. 2017 08; 92(8):1304-1311. View in: Pubmed
-
Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. J Thorac Oncol. 2017 05; 12(5):e51-e55. View in: Pubmed
-
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Med Oncol. 2017 Jun; 34(6):105. View in: Pubmed
-
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol. 2017 Jun; 9(6):387-404. View in: Pubmed
-
The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opin Drug Saf. 2017 Jan; 16(1):101-109. View in: Pubmed
-
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland. Tumori. 2016 Nov 11; 102(Suppl. 2). View in: Pubmed
-
Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient. J Breast Cancer. 2016 Sep; 19(3):324-329. View in: Pubmed
-
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? ESMO Open. 2016; 1(4):e000022. View in: Pubmed
-
Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. Clin Drug Investig. 2016 Aug; 36(8):683-6. View in: Pubmed
-
Targeting EGFR and ALK in NSCLC: current evidence and future perspective. Lung Cancer Manag. 2016 Jun; 5(2):79-90. View in: Pubmed
-
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series. J Neurooncol. 2016 09; 129(2):355-61. View in: Pubmed
-
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer. 2016 May; 95:82-7. View in: Pubmed
-
Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy. Med Oncol. 2016 Feb; 33(2):18. View in: Pubmed
-
Double aortic arch with right positioned descending thoracic aorta and coexistent aortic kinking. BMJ Case Rep. 2015 Dec 14; 2015. View in: Pubmed
-
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Rev Respir Med. 2016; 10(1):53-68. View in: Pubmed
-
Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. Expert Opin Pharmacother. 2015; 16(17):2601-13. View in: Pubmed
-
Melanosis coli or ischaemic colitis? That is the question. BMJ Case Rep. 2015 Sep 04; 2015. View in: Pubmed
-
miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance. Ecancermedicalscience. 2015; 9:569. View in: Pubmed
-
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report. Ecancermedicalscience. 2015; 9:559. View in: Pubmed
-
Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015 Mar; 87(3):211-9. View in: Pubmed
-
Non-coding RNAs in lung cancer. Oncoscience. 2014; 1(11):674-705. View in: Pubmed
-
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Clin Lung Cancer. 2014 Jan; 15(1):86-92. View in: Pubmed
Locations

Dana-Farber Cancer Institute
450 Brookline Avenue Boston, MA 02215Dana-Farber Cancer Institute
